MedTrace Logo

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

NCT00948389 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-08-31

Study results available
· View outcomes & findings →

Summary

To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma

Conditions

Interventions

DRUG

Dasatinib

Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity

DRUG

Lomustine

Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • Bristol-Myers Squibb

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • France
  • Italy
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00948389 on ClinicalTrials.gov